Opendata, web and dolomites

MIRCAB

Validation of diagnostic and/or prognostic miRNAs in triple-negative breast cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MIRCAB" data sheet

The following table provides information about the project.

Coordinator
MULTIPLICOM NV 

Organization address
address: GALILEILAAN 18
city: NIEL
postcode: 2845
website: www.multiplicom.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2015-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MULTIPLICOM NV BE (NIEL) coordinator 50˙000.00

Map

 Project objective

Multiplicom will draft a business plan that is composed of the following parts: (i) selection of miRNAs for which there is substantial scientific evidence that such may be important for the diagnosis, treatment and/or prognosis of triple-negative breast cancer (“TNBC”) patients; (ii) perform a thorough analysis of the intellectual property on the selected miRNAs; (iii) start in-licensing negotiations with licensors regarding relevant intellectual property (iv) select a suitable quantitative multiplex miRNA analysis; (v) plan a European-wide, multi-center, clinical validation of the selected miRNAs using the selected multiplex quantification method (“Validation Study”); and (vi) perform a marketing study regarding the use of miRNA diagnosis/prognosis in TNBC patients; (vii) develop a competitive strategy

For part (i) Multiplicom has the support of top-notch clinical scientists (“KOLs”) in the field of miRNA in TNBC. Multiplicom will rely on its internal expertise, and expertise of its consultants to perform (ii) to (vi). This is supported by its track record of developing and commercializing novel highly multiplexed diagnostics (ISO 13485 & CE/IVD).

The global 170,000 cases of TNBC (new cases in 2012) constitute the target patient population to be monitored by the validated multiplex miRNA test kit (“Kit”) such that they can be offered the best treatment of what is a multi-billion Euro pharmaceutical opportunity. From presently available data Multiplicom estimates the annual peak sales of the Kit in excess of €5M, with a gross margin of >80%, allowing further expansion of the company including new hires in all departments.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIRCAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIRCAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More